Your browser doesn't support javascript.
loading
Computer-aided design, synthesis, and biological evaluation of new indole-2-carboxamide derivatives as PI3Kα/EGFR inhibitors.
Sweidan, Kamal; Sabbah, Dima A; Bardaweel, Sanaa; Dush, Khadeja Abu; Sheikha, Ghassan Abu; Mubarak, Mohammad S.
Affiliation
  • Sweidan K; Department of Chemistry, The University of Jordan, Amman 11942, Jordan. Electronic address: k.sweidan@ju.edu.jo.
  • Sabbah DA; Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, PO Box 130, Amman 11733, Jordan. Electronic address: dima.sabbah@zuj.edu.jo.
  • Bardaweel S; Department of Pharmaceutical Sciences, Faculty of Pharmacy, The University of Jordan, Amman 11942, Jordan.
  • Dush KA; Department of Chemistry, The University of Jordan, Amman 11942, Jordan.
  • Sheikha GA; Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, PO Box 130, Amman 11733, Jordan.
  • Mubarak MS; Department of Chemistry, The University of Jordan, Amman 11942, Jordan.
Bioorg Med Chem Lett ; 26(11): 2685-90, 2016 06 01.
Article in En | MEDLINE | ID: mdl-27084677
ABSTRACT
Structure-based drug design and molecular modeling were employed to identify a new series of indole-2-carboxamides as potential anticancer agents. These compounds were synthesized and characterized with the aid of several spectroscopic techniques, such as FT-IR, NMR, and mass spectrometry as well as by elemental analysis. Molecular docking studies confirmed that the newly synthesized compounds accommodate PI3Kα and EGFR kinase catalytic sites and form H-bonding with the key binding residues. The antitumor activity of these new compounds against an array of cancer cell lines (human colon carcinoma (HCT116), leukemia (K562), and breast cancer (MDA231) was evaluated. Results revealed that these compounds were selective against the kinase domain, and none of them showed any inhibitory activity against K562. In addition, results showed that compound 13 exhibited high potency in HCT116 and MDA231 with IC50 values of 19 and 15µM, respectively. Our findings recommend that further optimization of this series would be beneficial for colon and breast cancer treatment.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Computer-Aided Design / Protein Kinase Inhibitors / ErbB Receptors / Phosphoinositide-3 Kinase Inhibitors / Indoles / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Year: 2016 Type: Article

Full text: 1 Database: MEDLINE Main subject: Computer-Aided Design / Protein Kinase Inhibitors / ErbB Receptors / Phosphoinositide-3 Kinase Inhibitors / Indoles / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Year: 2016 Type: Article